Crispr Therapeutics AG (CRSP) — Cash Flow-to-Debt Ratio
Crispr Therapeutics AG (CRSP) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2026, meaning its operating cash flow of $-108.90 Million could theoretically repay 0% of its total liabilities ($911.26 Million) in one year. See how much free cash does Crispr Therapeutics AG generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Crispr Therapeutics AG Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Crispr Therapeutics AG across 12 annual periods. Also explore CRSP net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Crispr Therapeutics AG (2014–2025)
Year-by-year debt coverage analysis for Crispr Therapeutics AG. For market capitalisation and broader financial context, see Crispr Therapeutics AG (CRSP) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.00x | $-345.01 Million | $343.43 Million | ▼ -118.1% |
| 2024 | -0.46x | $-142.77 Million | $309.95 Million | ▲ +38.7% |
| 2023 | -0.75x | $-260.38 Million | $346.77 Million | ▲ +44.3% |
| 2022 | -1.35x | $-495.74 Million | $367.58 Million | ▼ -188.2% |
| 2021 | 1.53x | $538.97 Million | $352.42 Million | ▲ +205.1% |
| 2020 | -1.46x | $-238.37 Million | $163.73 Million | ▼ -427.1% |
| 2019 | 0.45x | $56.68 Million | $127.33 Million | ▲ +144.8% |
| 2018 | -0.99x | $-96.24 Million | $96.82 Million | ▼ -18.4% |
| 2017 | -0.84x | $-70.10 Million | $83.51 Million | ▼ -70.1% |
| 2016 | -0.49x | $-55.31 Million | $112.12 Million | ▼ -256.5% |
| 2015 | 0.32x | $59.43 Million | $188.55 Million | ▲ +155.9% |
| 2014 | -0.56x | $-4.79 Million | $8.50 Million | — |